Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.81 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26079021 | 0.99 | HDAC6 (0.79) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL15725473 | 0.92 | HDAC6 (0.85) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL17955695 | 0.91 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL15725463 | 0.90 | HDAC6 (0.82) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL15725397 | 0.90 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| Ricolinostat SCHEMBL574580 | 0.90 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL10050234 | 0.88 | HDAC6 (0.82) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL21707466 | 0.88 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2224178 | 0.88 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC7HDAC2 | |
| SCHEMBL2223535 | 0.87 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180036306-A1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES | ACETYLON PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170114023-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20160355486-A1 | METHODS OF MAKING PROTEIN DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9403779-B2 | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| US-8394810-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC1 1/4885HDAC3 10/4885 |
| US-20160355486-A1 | METHODS OF MAKING PROTEIN DEACETYLASE INHIBITORS | HDAC1, HDAC6, AADAC | HDAC6 2/4885HDAC1 1/4885HDAC3 4/4885 |
| US-20170114023-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | HDAC6 9/4885HDAC1 4/4885HDAC3 7/4885 |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | HDAC6 9/4885HDAC1 4/4885HDAC3 7/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC1 1/4885HDAC3 10/4885 |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC3 3/4885 |
| US-20180036306-A1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES | HDAC6, HDAC5, HDAC2 | HDAC6 1/4885HDAC1 5/4885HDAC3 12/4885 |
| US-20140142117-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.